RxDoctor Payments Data

Stacy Wagner, PA

Medical · Wichita, KSNPI 1992054431

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.7% of the total across 251 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by AbbVie at 25.0% of the total. Reporting peaked in 2022 at $1,880 and has fallen 92.9% since, to $133 in 2024.

$4,213in general payments, 2019–2025

Across 251 payments — averaging $16.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$597
  • Pfizer$459
  • Amgen$435
  • AstraZeneca$267
  • UCB, Inc.$231
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$4,11498%
  • Education$992%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie69$1,055
Johnson & Johnson30$597
Pfizer33$459
Amgen(2 entities)26$435
AstraZeneca(2 entities)15$267
UCB, Inc.10$231
Genentech USA, Inc.14$183
Novartis12$170
GSK13$170
Lilly USA, LLC7$134
Aurinia Pharma U.S., Inc.5$91
ANI Pharmaceuticals, Inc.4$86
Mallinckrodt Hospital Products Inc.4$84
Boehringer Ingelheim2$81
Organon1$31
Fresenius Kabi USA, LLC1$27
CSL Behring1$26
Biocon Biologics Inc1$25
Sobi, Inc1$24
Mylan Institutional Inc.1$20
Takeda Pharmaceuticals U.S.A., Inc.1$16

How this compares

$4,213 in reported general payments places this provider in the 80th percentile of 205 medical providers in Kansas.

See all medical providers in Kansas

Medicare billing

Part B allowed, 2024
$16,786
Medicare patients
103
Services billed
386

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide13$11,749
JardianceEmpagliflozin19$10,966
Cinacalcet Hcl11$4,764
Hydroxychloroquine Sulfate104$2,425
MethotrexateMethotrexate Sodium50$1,117
Sulfasalazine50$902
Pregabalin27$500
Gabapentin48$395
Pantoprazole Sodium18$321
Leflunomide11$285
Metoprolol Succinate53$270
Losartan Potassium51$234
Potassium Chloride11$232
Levothyroxine Sodium45$223
Duloxetine Hcl18$214

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$81$10,96619 claims
Lilly USA, LLCOlanzapine$134$5711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 205 medical providers in Kansas.

Other medical in Wichita

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →